Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Labskin, a global leader in laboratory-grown human skin models used for research, testing and product development.
The partnership follows a series of successful shipping trials, demonstrating Atelerix’s non-cryogenic preservation technology is able to maintain the structural integrity and viability of Labskin’s 3D constructs well beyond the traditional 72-hour to 96-hour transport window.
Labskin develops full-thickness human skin models for testing applications spanning skincare, cosmetics, healthcare, drug delivery and wound care.
These physiologically-relevant models mimic the skin’s delicate microbiome, and therefore require careful shipping considerations.
Through an initial Memorandum of Understanding (MoU), the agreement establishes a collaborative framework to validate and implement Atelerix’s hypothermic hydrogel technology for the extended-duration shipment of these advanced skin model systems.
Extending the viable shipping period provides a significant logistical advantage for Labskin, reducing risk associated with customs delays and enabling reliable distribution to customers and further expansion across key global markets.
Atelerix’s patented hydrogel technology preserves membrane integrity and biological function at ambient or controlled temperatures, delivering a ready-to-use product upon arrival and avoiding the complications and resource demands of cold-chain transport.
The MoU with Labskin follows in a series of strategic partnerships as the company broadens global access to its preservation solutions across Europe, Africa, Asia and North America.
Together, the companies will continue the collaborative optimisation of workflows and pursue joint opportunities for external engagement to demonstrate how next-generation preservation can transform the shipping and handling of complex biological materials.
